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Abstract: Prescription of mucoactive drugs for chronic obstructive pulmonary disease (COPD) 
is increasing. This development in clinical practice arises, at least in part, from a growing 
understanding of the important role that exacerbation frequency, systemic inﬂ  ammation and 
oxidative stress play in the pathogenesis of respiratory disease. S-carboxymethylcysteine (car-
bocisteine) is the most frequently prescribed mucoactive agent for long-term COPD use in the 
UK. In addition to its mucoregulatory activity, carbocisteine exhibits free-radical scavenging and 
anti-inﬂ  ammatory properties. These characteristics have stimulated interest in the potential that 
this and other mucoactive drugs may offer for modiﬁ  cation of the disease processes present in 
COPD. This article reviews the pharmacology, in vivo and in vitro properties, and clinical trial 
evidence for carbocisteine in the context of guidelines for its use and the current understanding 
of the pathogenic processes that underlie COPD.
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Introduction
S-carboxymethylcysteine (carbocisteine or SCMC) is a mucoactive drug with in vitro 
free-radical scavenging and anti-inﬂ  ammatory properties. Carbocisteine was ﬁ  rst 
synthesized in the 1930s and became available for use as a mucoregulator in respiratory 
disease in the 1960s. A lack of consistency in data on clinical efﬁ  cacy resulted in 
diminished use in the UK, and National Health System (NHS) formulary blacklisting 
in the 1980s. Throughout this time, prescribing of mucolytic/mucoactive agents for 
short- and long-term use remained common in Europe. However, a new understanding 
of the importance of exacerbation frequency in the progression of chronic obstruc-
tive pulmonary disease (COPD) and the role of systemic inﬂ  ammation in the disease 
process, together with publication of several trials demonstrating positive effects of 
mucoactive drugs on exacerbation rates and quality of life, have rekindled interest 
in this family of drugs. There is increasing evidence that drugs commonly used for 
their mucoactive properties have diverse mechanisms of action, including signiﬁ  cant 
anti-oxidant activity. In light of the well-established role of oxidative stress in the 
pathogenesis of COPD, it seems plausible that when these drugs are used over the 
long term they may modify the disease process. Carbocisteine became available by 
NHS prescription for chronic use in COPD once again in 2003.
Carbocisteine: pharmacology
Carbocisteine is available as an oral preparation both, as SCMC and its lysine salt 
(SCMC-Lys). The lysine group is cleaved on gastric absorption to form the active 
drug SCMC. Carbocisteine is a blocked thiol derivative of amino-acid; L-cysteine. International Journal of COPD 2008:3(4) 660
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The structure and mechanism of action of carbocisteine 
differs from other commonly available mucolytic drugs such 
as N-acetylcysteine (NAC) and erdosteine that bear free 
sulfhydryl (thiol) groups via which they split glycoprotein 
bonds in mucus.
Carbocisteine is well absorbed when taken orally, 
demonstrating one compartment open model kinetics 
thereafter. Peak serum concentrations are achieved at 1 to 
1.7 hours and the plasma half-life is 1.33 hours. It achieves 
good penetration into lung tissue and bronchial secretions 
(Servin et al 1976; Braga et al 1982).
Approximately 30% to 60% of the drug is excreted 
unchanged in urine. Metabolic pathways are particularly 
complex with great inter-individual variation. They include 
acetylation, decarboxylation and sulfoxidation to produce 
inactive derivatives. Hepatic cytosolic sulfoxidation 
produces metabolites, which do not have the free-radical 
scavenging properties of the sulﬁ  de parent compound. 
Metabolism in this manner demonstrates a diurnal variation 
with less sulfoxidation occurring at night. There is also 
considerable variability in metabolism between individuals 
due to a genetic polymorphism in sulfoxidation capacity. 
Less efﬁ  cient metabolism may result in increased exposure 
to the active parent compound and has been cited as one 
explanation for the inconsistent clinical response seen 
between individuals receiving the drug (Waring 1988; 
Steventon and Mitchell 2006).
There has been interest in the selection of patients for 
therapy on the basis of their metabolic activity for many 
years. In current practice, response is established on 
clinical grounds after a trial period, and non-responders 
are instructed to discontinue the drug. It is unclear whether 
those with seemingly appropriate clinical indications for 
carbocisteine who do not experience an improvement 
with its initiation are active sulfoxidizers and whether 
they might respond to a higher dose or nocturnal dosing 
regimens.
There is a theoretical risk of gastric erosion in the con-
text of alterations in the characteristics of gastric mucus 
with all mucolytic agents. Carbocisteine is, therefore, 
contraindicated in active gastric ulceration. No signiﬁ  cant 
toxicity has been reported either in animal models or fol-
lowing prolonged use in humans, and no drug interactions 
have been identiﬁ  ed. Mild side-effects (largely gastric dis-
comfort) are occasionally reported, eg, 1.8% of patients in 
the treatment arm of one large study (Allegra et al 1996). 
Fixed drug eruption has also been infrequently associated 
with long-term prescribing of carbocisteine. It has been 
proposed that exposure to metabolic products, such as 
thiodiglycolic acid, may be responsible for this response. 
Thiodiglycolic acid is produced in greater concentration in 
poor sulfoxidizers, and so these reactions (ie, cutaneous) 
may be more common in this patient group (Steventon and 
Mitchell 2005).
Dose regimens for carbocisteine vary internationally, 
ranging from 750 mg twice daily to 4.5 g once daily. 
There is little evidence to advocate one particular dosing 
regimen, although (as previously discussed) nocturnal 
administration may achieve higher concentrations of the 
active compound.
Targets for carbocisteine in COPD: 
natural history and the role 
of oxidative stress
COPD manifests as airway obstruction that is not fully 
reversible and deteriorates over time, at a rate greater than 
that seen with advancing age. The underlying disease 
process affects both the airways and interstitial lung tissue. 
Airway abnormalities include smooth muscle hypertrophy, 
mucus accumulation, wall thickening with neutrophil and 
inﬂ  ammatory inﬁ  ltrate, and an increase in number and size 
of goblet cells. The accompanying clinical syndrome of 
chronic bronchitis frequently co-exists with emphysema (the 
interstitial component) under the umbrella term of COPD. 
Central to the development and progression of the disease is 
a process of oxidative stress and proteinase–antiproteinase 
imbalance that frequently becomes self perpetuating 
(Repine 1997).
Oxidants derived from cigarette smoke and other 
environmental pollutants, in addition to those produced 
as a result of neutrophilic inflammation, inactivate 
antiproteinases (particularly α1-antitrypsin). This results in 
uncontrolled elastase activity and pulmonary tissue destruc-
tion, both by direct toxicity to protein and lipid structures 
and via the up-regulation of interleukin-8 (IL-8) activity. 
Elastase promotes the conversion of endogenous pulmo-
nary xanthine dehydrogenase to xanthine oxidase, which 
acts on purine substrates and molecular oxygen to produce 
superoxide; a process that is central to oxidative stress in 
many inﬂ  ammatory lung diseases.
Oxidants also exert a directly toxic effect on the 
structures of the lung, impair cilial activity and increase 
mucus production by goblet cells (Adler et al 1990; Feldman 
et al 1994).
Ongoing neutrophil and free-radical induced inﬂ  ammation, 
along with the accumulation of tenacious mucus and airway International Journal of COPD 2008:3(4) 661
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remodeling with smooth muscle hyperplasia, results in 
increasing airﬂ  ow limitation and creates an environment 
conducive to bacterial colonization. This, in itself, 
contributes to persistent inﬂ  ammation and to neutrophil 
and alveolar macrophage recruitment to the airways, and 
is associated with a greater severity of airﬂ  ow obstruction 
(Soler et al 1999; Zalacain et al 1999).
There is increasing evidence that COPD is a disease 
of systemic inflammation and that deterioration in 
parameters other than forced expiratory volume in one 
second (FEV1) predict outcomes with greater sensitivity. 
Muscle dysfunction, both peripheral and diaphragmatic, is 
an important contributor to decline in patients with COPD. 
Quadricep strength and maximum inspiratory pressure 
generation have been shown to be predictors of mortality in 
moderate and severe COPD (Swallow et al 2007; Ottenheijm 
et al 2008). Elevated markers of oxidative stress have been 
demonstrated in the diaphragms of patients with severe 
COPD, and levels of protein oxidation have a negative 
correlation with respiratory muscle strength (Barreiro et al 
2005). Peripheral muscles, particularly of the lower limbs, 
are also exposed to increased levels of both oxidative and 
nitrosative stress (Barreiro et al 2003). Both muscle groups 
demonstrate shifts in ﬁ  ber type and atrophy that can be 
partially attributed to chronic inﬂ  ammation and free-radical 
activity (Ottenheijm et al 2008).
Outcomes of relevance to disease progression in COPD 
have only been deﬁ  ned in recent years. Older studies tended 
to focus on lung function, a measure now thought to be a less 
useful marker of disease. Outcomes for the results of clinical 
interventions in COPD that are now thought to be relevant 
include: exacerbation rates; days of illness and hospital bed 
days; rate of lung function and exercise tolerance decline; all 
cause mortality; and improvement in health-related quality 
of life.
Acute exacerbations of COPD often occur in response 
to bacterial or viral infection and are recognized as 
deterioration in a patient’s respiratory symptoms, frequently 
requiring additional treatment. Exacerbations incur 
signiﬁ  cant healthcare costs and contribute to decline in 
patients’ health-related quality of life (Seemungal et al 
1998). Donaldson et al ﬁ  rst established that more frequent 
exacerbations of COPD are associated with a greater rate   
of decline in lung function parameters (Donaldson et al 
2002). It is recognized that some COPD patients experience 
frequent exacerbations, yet in others the disease takes a 
more stable course. Following many exacerbations, clinical 
and physiological state fails to return to baseline, and 
systemic inﬂ  ammation continues on at a heightened level 
(Seemungal et al 2000).
Clinical application 
of mucoactive drugs in COPD
The 2006 Cochrane meta-analysis of mucolytic agents 
for COPD included 26 placebo-controlled, randomized 
clinical trials (RCTs) involving 7,335 patients (Poole and 
Black 2006). SCMC, SCMC-Lys and SCMC-sobrerol 
were included in only 3 of the trials, comprising a total 
of 486 subjects. The majority of the evidence included in 
the meta-analysis concerned NAC, the most widely used 
mucolytic agent internationally. The review concluded that 
there was evidence for a statistically signiﬁ  cant reduction in 
the number of exacerbations per patient with long-term use 
(greater than 2 months) of oral mucolytics, of the order of 
20% (0.5 exacerbations per patient per year). Overall, days 
of disability were reduced to a greater extent in the sub-set 
of intervention groups where this outcome was reported. 
Patients receiving mucolytics were more likely to experience 
no exacerbations than those receiving placebo, with a number 
needed to treat (NNT) of 6. There is variability between the 
studies in reported changes in lung function parameters, 
which precludes a ﬁ  rm conclusion on the effect of mucolytics 
on spirometric parameters. Few of the studies included had 
measured health-related quality of life using validated tools 
and only one, concerning the use of erdosteine, demonstrated 
a signiﬁ  cant improvement with the drug compared with 
placebo (Moretti et al 2004). The Cochrane review did not 
reveal a signiﬁ  cant variation in outcome measures between 
different mucolytic agents and no serious adverse events were 
reported within the pooled data. The authors state that: “it is 
unlikely that the magnitude of the impact on exacerbation 
rates reported in the review will translate to COPD patients 
receiving current standard care”. Firstly, it is assumed that 
many of the study patients will not have received inhaled 
corticosteroids (ICS), which were not in routine use in COPD 
prior to 1990, although this information is not speciﬁ  cally 
provided for many of the trials. Secondly, a great proportion 
of the studies were conducted over the winter period, during 
which exacerbation rates peak. The impact of mucolytic 
agents on the lower summer exacerbation rates is likely to 
be less impressive. The 2006 Cochrane review also raised 
the possibility of economic value in restricting mucolytic use 
exclusively to the winter months.
Supported by the National Institute for Health and 
Clinical Excellence (NICE) and British Thoracic Society 
(BTS) guidelines, mucolytic agents are currently in use International Journal of COPD 2008:3(4) 662
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selectively in COPD patients. The single available study on 
the cost-effectiveness analysis of mucolytics (speciﬁ  cally 
NAC) in COPD does not support prescribing in unselected 
patients with COPD (Grandjean et al 2000). At this time, 
there is a greater weight of evidence for their use in patients 
who exacerbate frequently and produce sputum chronically. 
Patients with significant symptoms related to sputum 
production, but who have mildly obstructive spirometry and 
therefore do not fulﬁ  l criteria for ICS, are likely to have the 
most to gain in terms of exacerbation reduction. This repre-
sents a small minority of COPD patients presenting to medical 
services. In practice, patient-reported improvement in symp-
toms related to sputum clearance and infective exacerbations 
is used to guide continuation with a mucolytic agent. In the 
clinical setting, most physicians are reluctant to temporarily 
suspend (ie, over the summer months) a safe intervention that 
has been associated with symptomatic relief.
Available mucolytic agents have been shown to have 
additional anti-inﬂ  ammatory and anti-oxidant activities. In 
theory, therefore, they offer the potential to modify the disease, 
beyond aiding sputum clearance and reducing exacerbation 
rates. Clinical evidence to this effect would support their 
broader application in COPD. The Bronchitis Randomised on 
N-acetylcysteine Cost-Utility Study (BRONCUS) sought to 
examine aspects of this hypothesis in an RCT comparing NAC 
600 mg daily with placebo, in 523 patients over a 3-year period 
(Decramer et al 2005). The study, the longest of its kind, dem-
onstrated no signiﬁ  cant differences in lung function decline, 
exacerbation rates or deterioration in health status between 
patients in the treatment and placebo arms, except in the sub-
group of patients not receiving ICS as standard management. 
No sufﬁ  ciently long-term studies have been conducted with 
carbocisteine to speciﬁ  cally examine modiﬁ  cation of disease 
progression or mortality as an outcome measure.
In vitro, ex vivo and in vivo 
properties of carbocisteine
Mucoregulation and effects 
on sputum clearance
The viscoelastic properties of bronchial mucus are 
determined by glycoproteins (namely fucomucins, 
sialomucins and sulfomucins). Higher concentrations of 
fucomucins are found in the sputum of patients with COPD 
(Lamblin et al 1977).
Carbocisteine resets the balance between sialomu-
cins and fucomucins (increasing concentrations of the 
former and reducing the latter) probably via the intracellular 
stimulation of sialyl transferase activity (Havez et al 1977). It 
is not thought to act on the structure of mucus once secreted 
into the airways in contrast to true mucolytic agents such as 
NAC. There is evidence from animal models that carbociste-
ine increases chloride transport across the airway epithelium 
and this may also contribute to its mucoregulatory action 
(Colombo et al 1994).
Several studies have demonstrated a reduction in 
measured sputum viscosity as early as 4 days after treatment 
initiation (Edwards et al 1976; Braga et al 1990). Braga 
et al examined the sputum viscosity and elasticity of 
53 patients with chronic bronchitis when treated with 4.5 g 
of carbocisteine daily for 5 days compared with placebo 
(Braga et al 1989). There were signiﬁ  cant reductions in 
both sputum characteristics with carbocisteine in patients 
with initial sputum viscosity and elasticity above the mean 
value previously established in similar patient groups. There 
is also in vivo and in vitro evidence of increased muco-
ciliary clearance velocity with carbocisteine, particularly 
in patients with slow clearance before treatment (Kohler 
et al 1982; Braga et al 1990). This, apparently selective, 
action supports a mucoregulatory mechanism and, in clini-
cal practice, supports the careful selection of patients for 
treatment with carbocisteine when it is prescribed for a pos-
sible symptomatic beneﬁ  t associated with enhanced sputum 
clearance. Signiﬁ  cantly, there are, also negative studies 
examining changes in sputum characteristics, in which 
different laboratory methods were employed (Thompson 
et al 1975; Goodman et al 1978). One explanation for this 
inconsistency is small study sample sizes combined with the 
inter-individual variability in response to the drug seen in 
clinical practice. However, there is also a lack of evidence 
correlating measurable mucoactive, drug-induced changes in 
sputum characteristics with clinical beneﬁ  t. It is therefore not 
clear, when beneﬁ  t is demonstrated, whether the mucoactive 
component to drug action should be credited. It should also 
be noted that in vitro studies of sputum viscosity are difﬁ  cult 
to standardize and a commonly accepted methodology has 
not been derived.
There is evidence that carbocisteine increases the 
penetration of amoxicillin into bronchial secretions of 
patients with bacterial exacerbations of chronic bronchitis 
when the drugs are used concomitantly. This effect is 
probably due to the alterations in glycoprotein composition 
of sputum (Braga et al 1985). Improving antibiotic delivery 
to the site of bacterial infection may have a valuable effect, 
but the speciﬁ  c clinical implications of this ﬁ  nding on acute 
infective exacerbations have not been fully studied.International Journal of COPD 2008:3(4) 663
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Actions on damaged epithelium 
and cough sensitivity
Evidence from animal models of respiratory epithelial 
repair demonstrates that carbocisteine reverses neutral 
endopepsidase levels and reduces cough sensitivity (but 
not methacholine-induced bronchoconstriction) in rodents 
with antigen-damaged tracheal epithelium in a dose-related 
manner (Katayama et al 2001). Neutral endopeptidase is a cell 
membrane bound enzyme that modulates tachykinin-induced 
potentiation of: cholinergic motor transmission; smooth 
muscle contraction; mucus secretion; cough, and increases in 
vascular permeability in the airways. It has been repeatedly 
demonstrated in both human and animal studies that 
neutral endopeptidase levels are reduced in the presence 
of respiratory epithelial injury and associated bronchial 
hyper-responsiveness (Cheung et al 1992; Cheung et al 1993). 
Ishiura et al performed a double-blind, placebo-controlled, 
cross-over trial that illustrated a significant reduction 
in cough sensitivity to inhaled capsaicin (a C-ﬁ  ber type 
bronchial cough receptor stimulator) in asthma patients 
following a 4-week course of carbocisteine (Ischiura et al 
2003). The investigators proposed that an increase in 
neutral endopeptidase levels could explain this drug effect 
and that carbocisteine may have a role in the treatment 
of cough-variant asthma and other inﬂ  ammatory airways 
disease in which intractable cough is a feature.
Action on respiratory pathogens
Attachment of pathogens to the respiratory epithelial cell 
surface is the ﬁ  rst step in the development of acute respiratory 
tract infections, most of which are initiated by colonization 
of the pharynx.
One possible mechanism by which carbocisteine has the 
potential to reduce bacterial respiratory tract infections in 
COPD is the inhibition adherence of pathogenic bacteria to 
cells. In vitro studies have demonstrated a signiﬁ  cant reduc-
tion in adherence of Moraxella catarrhalis to the pharyngeal 
epithelial cells, of both healthy subjects and those with 
chronic bronchitis treated with carbocisteine, when compared 
with placebo (Zheng et al 1999). Similarly, attachment of 
Streptococcus pneumoniae to pharyngeal epithelial cells 
taken from healthy subjects has been shown to be reduced 
by direct in vitro treatment of the cells with carbocisteine 
(Cakan et al 2003). It has been proposed that disruption of 
bacterial receptor sites on the epithelial surface and within 
mucus may explain these ﬁ  ndings.
Rhinoviruses are associated with exacerbations of 
COPD. They increase oxidative stress and the production of 
inﬂ  ammatory mediators. Intercellular adhesion molecule-1 
(ICAM-1) is required for entry of rhinovirus ribonucleic 
acid (RNA) into cellular endosomes. Circulating ICAM-1 
is present in greater concentrations in COPD and may have 
a role in neutrophil recruitment and retention in the lung, in 
addition to increasing susceptibility to viral respiratory tract 
infections (Riise et al 1994). Carbocisteine reduces expres-
sion of ICAM-1 and has been associated with a reduction in 
frequency of common colds and associated exacerbations in 
COPD patients (Tatsumi 2007).
Anti-oxidant and anti-inﬂ  ammatory 
activity
As discussed, airway inﬂ  ammation and oxidative stress due 
to inﬂ  ammation, infection, inhaled environmental pollutants 
and (particularly) cigarette smoke plays a signiﬁ  cant part in 
the development and progression of COPD.
Animal studies have demonstrated the anti-inﬂ  amma-
tory action of carbocisteine in models of induced pulmo-
nary inﬂ  ammation involving several different cytokine 
proﬁ  les. Oral pre-treatment with SCMC-Lys appears to 
attenuate neutrophil recruitment in acute IL-1β-induced 
airway inflammation and neutrophil, macrophage and 
eosinophil migration to the pleural space in carrageenan 
induced pleurisy (Asti et al 1995). Administration of 
carbocisteine to rats with sulfur dioxide-induced airway 
inﬂ  ammation attenuates the secretion of abnormal mucous 
glycoproteins and reduces inﬂ  ammatory cells, free radical 
and elastase activity in their bronchoalveolar lavage (BAL) 
ﬂ  uid (Ishibashi et al 2001).
Carbocisteine has been shown to have relevant in vitro 
free-radical scavenging properties. NAC is recognized as a 
mucolytic agent with anti-oxidant behavior that is exerted 
via its free thiol group to form NAC disulﬁ  de. In contrast, 
carbocisteine does not carry a free thiol group but its thioether 
group can be oxidized by reactive oxygen species to form the 
sulfoxide by-product; however its anti-oxidant mechanism 
is not yet fully understood. Pinamonti et al conducted a 
series of experiments in 3 oxygen radical-producing systems 
(Pinamonti et al 2001). The experiments demonstrated that 
the addition of carbocisteine to the BAL ﬂ  uid of stable COPD 
patients markedly reduced lymphocyte DNA destruction 
and reduced oxidative activity (measured as reduced cyto-
chrome c concentration) of the solution in a dose-dependent 
manner. Free radical damage to deoxyribonucleic acid 
(DNA) in ultrasound-treated human serum was also reduced 
by the addition of carbocisteine. Finally, the concentration 
of xanthine oxidase products (superoxide and uric acid) International Journal of COPD 2008:3(4) 664
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in the supernatant of endothelial cells cultured with elastase 
was signiﬁ  cantly reduced by the addition of carbocisteine 
to the culture.
Activated neutrophils produce a range of free radicals, 
with hydroxyl radical (OH−) and hypochlorus acid (HOCl) 
being the most potent in terms of tissue injury. HOCl in 
particular oxidizes the methionyl residues of α1-antitrypsin, 
inactivating it and resulting in uncontrolled neutro-
phil elastase action. Intracellular production of OH− is 
implicated in IL-8 production that, in turn, has a role in 
the up-regulation of protease activity (Deforge et al 1992). 
Brandolini et al examined the free-radical scavenging 
capacity and its mechanism of SCMC-Lys in cell-free and 
cellular solutions (Brandolini et al 2003). In the cell-free 
studies, SCMC-lys demonstrated a potent, concentration-
dependent reducing effect on NaOCl and HOCl, with 
resultant oxidation of the drug’s thioether group to form 
the sulfoxide (S−CMC = O). In this model, the reducing 
capacity of SCMC-Lys was equal to that of glutathione 
(the chief endogenous anti-oxidant). A SCMC-Lys 
concentration-dependent reduction of HOCl-mediated 
inhibition of α1-antitrypsin was also demonstrated. In the 
cellular studies, an equally potent free-radical scaveng-
ing action was demonstrated with OH− when a solution 
containing neutrophils and deoxyribose was combined 
with SCMC-Lys, which inhibited the selective oxidation 
of deoxyribose by neutrophil hydroxyl radicals. Finally, 
SCMC-Lys was shown to inhibit both paraquat- and 
IL-1β-induced IL-8 production by human peripheral blood 
mononuclear cells.
8-isoprostane is produced by the reaction of oxygen 
radicals with arachidonic acid and other endogenous 
polyunsaturated fatty acids. It can be measured in breath 
condensate as a marker of oxidative stress in the lung. 
Exhaled 8-isoprostane is signiﬁ  cantly elevated in stable, 
and to a greater extent exacerbating COPD (Montuschi 
et al 2000; Carpagnano et al 2004). Carpagnano et al 
demonstrated a signiﬁ  cant reduction in both exhaled 8-iso-
prostane and pro-inﬂ  ammatory cytokine, IL-6, in patients 
with COPD treated with SCMC-Lys for a 6-month period, 
providing an in vivo translation for the wealth of in vitro 
evidence that the drug has anti-inﬂ  ammatory and anti-oxi-
dant properties.
Long-term use of carbocisteine 
and SCMC-Lys in COPD
Clinical trial data on the use of carbocistiene in COPD are 
summarized in Table 1.
Several small studies conducted prior to 1990 compared 
2.25 g to 3.00 g carbocisteine daily with placebo in chronic 
bronchitis, examining the outcome measures of lung function, 
sputum characteristics and symptom scores (Aylward 
1974; Edwards et al 1976; Puchelle et al 1976; Grillage and 
Barnard-Jones 1985). Reported impact on lung function 
parameters is variable, but effect on the more subjective 
measures of cough and dyspnea resolution, and on increased 
sputum clearance is more consistently positive. These studies 
did not use well-validated outcome measures, and duration 
of carbocystiene administration varied from 10 days to 
6 months, making it difﬁ  cult to draw general conclusions 
about their clinical relevance.
Exacerbation rate has been demonstrated to have a 
signiﬁ  cant impact on disease progression and health-related 
quality of life in COPD (Seemungal 1998). It therefore 
represents a relevant and deﬁ  nable outcome measure in 
clinical trials.
Four systematically-blinded and randomized studies 
comparing SCMC/SCMC-Lys with placebo and using 
exacerbations as the primary outcome measure have been 
reported. Allegra et al (1996) conducted their study over a 
6-month period during the winter. Their 662 patients had 
baseline lung function suggestive of mild-to-moderate 
COPD. ICS were not excluded, but the proportion of 
patients in each group on ICS as standard treatment is 
not stated. The baseline FEV1 of the placebo group was 
significantly lower than that of the treatment group. 
Patients who received carbocisteine were signiﬁ  cantly 
more likely to remain exacerbation free than the placebo 
group (χ2 13.98, p = 0.001). A large proportion of all 
study patients remained exacerbation-free (54.0% in the 
placebo group compared with 70.4% in the continuous 
SCMC-Lys treatment group). Mean time to ﬁ  rst exacerba-
tion was signiﬁ  cantly prolonged in the treatment group (96 
days compared with 130 days). There was a statistically 
signiﬁ  cant reduction in mean days of acute respiratory 
illness per patient (3.8 ± 7.4 days compared with 6.7 ± 
9.7 days) with an equivalent reduction in days of antibiotics 
required. There were no statistically signiﬁ  cant effects of 
intermittent treatment with carbocisteine compared with 
results in patients receiving placebo. The total number of 
exacerbations during the study period for each group was 
not reported (Allegra et al 1996).
An earlier double-blind, parallel-group study carried out 
in the UK examined the impact of 750 mg carbocisteine 
3 times daily compared with placebo on peak ﬂ  ow and 
exacerbation rate in 109 patients with chronic bronchitis International Journal of COPD 2008:3(4) 665
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(Medical Research Council defined) over 6 winter 
months (Grillage and Barnard-Jones 1985). The baseline 
characteristics of the groups are reported to be well matched, 
although no speciﬁ  c baseline statistics (including drug 
therapy at trial entrance) are listed. There was no demon-
strable signiﬁ  cant difference in exacerbation rate between 
treatment groups.
In a Japanese trial, Yasuda et al compared carbocisteine 
1.5 g daily with placebo in 156 patients with COPD over a 
12-month period (Yasuda et al 2006). The subjects tended 
to have mild COPD, and the 2 trial groups demonstrated 
no signiﬁ  cant differences in baseline characteristics. Of 
note, no patients received ICS or oral corticosteroids during 
the study. There was a statistically signiﬁ  cant reduction in 
the number of common colds (as deﬁ  ned by a validated 
10-point symptom scoring system) in the carbocisteine 
group (1.69 ± 0.18 compared with 3.14 ± 0.35, relative risk 
[RR] 0.40 [95% CI 0.20–0.80]). The exacerbation rate was 
also signiﬁ  cantly reduced in the treatment group: RR 0.30 
(95% CI 0.20–0.70). Mean exacerbations per patient per 
year were 0.54 ± 0.11 in the treatment group compared with 
1.38 ± 0.20 for placebo.
Most recently, the well-powered and systematically 
conducted Chinese PEACE study has demonstrated a 
clinically and statistically signiﬁ  cant reduction in exac-
erbation rates in patients with moderate-to-severe COPD 
receiving carbocisteine over a 12-month period compared 
with placebo. A mean reduction of 0.34 exacerbations 
per patient per year was recorded in the treatment group 
(receiving 500 mg carbocisteine 3 times a day for a 
12-month period) compared with placebo (Zheng et al 
2008). Reduction in the rate of exacerbations only became 
signiﬁ  cant after 6 months of treatment. Quality of life 
measures were also signiﬁ  cantly improved at 12 months, 
consistent with the reduction in exacerbations. The study 
demonstrates the value of long-term carbocisteine in 
Chinese patients with COPD, but these results cannot be 
directly applied to European populations. Routine treat-
ment for COPD in China includes the early prescription 
of methyl-xanthines and minimal use of ICS. In the study 
group, only 16.7% received ICS and, although this sub-
group also demonstrated beneﬁ  t from carbocisteine, it is 
likely that far lower-dose corticosteroids were in use than 
those routinely prescribed in Europe.
Conclusions
Carbocisteine exhibits a wide range of in vitro and in 
vivo anti-inflammatory and anti-oxidant activities in both 
human and animal models. In certain circumstances, it 
may diminish inflammatory cell recruitment to the air-
ways, attenuate endothelial injury and associated cough 
sensitivity, and act as a potent, free-radical scavenger. 
These actions, in parallel with its mucoregulatory func-
tion, have theoretical relevance to pathogenic processes 
in COPD and other inflammatory airways disease. 
Clinical studies of carbocisteine in COPD examining the 
outcome measures of exacerbation rate and lung func-
tion parameters have produced heterogeneous results, 
reflecting those from studies with other mucolytic agents. 
Historically, trials have selected cohorts of patients with 
mild-to-moderate COPD, and there is circumstantial 
evidence that the impact of mucolytic and anti-oxidant 
agents is greater in patients who are not receiving ICS 
as standard management – an increasingly small group. 
There has not yet been a trial specifically focused on 
carbocisteine of adequate duration to answer questions 
about its direct impact on disease progression or survival 
in COPD. Results from the BRONCUS concerning NAC 
were inconclusive when these outcomes were considered 
(Decramer et al 2005).
Currently, the place for carbocisteine in COPD 
remains as a well-tolerated treatment with a favorable 
safety profile that provides symptomatic relief to some 
patients with sputum production, and that may reduce 
exacerbation rates via a range of mechanisms. Many 
uncertainties about carbocisteine remain. These include 
the relative clinical importance of its numerous mecha-
nisms of action, appropriate patient selection and optimum 
dosing regimens (particularly to exploit the drug’s anti-
oxidant and anti-inflammatory activities). The majority 
of the evidence for carbocisteine’s action is extrapolated 
from in vitro studies. To date, there are limited data 
from large randomized trials examining the effect of the 
addition of carbocisteine to existing treatment regimens, 
and so use of mucolytics is still largely based on clinical 
judgement and observation of symptomatic benefits in 
selected patients.
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Table 1 Summary of some of the clinical trial data published on carbocisteine (SCMC)
Reference Study design Diagnostic category Mean baseline FEV1 
(L/sec)
Study size
Aylward 1973 Double-blind RCT Chronic bronchitis SCMC 43.8% ± 3.6 n = 30
Bromhexine 46.3% ± 4.9
Aylward 1974 Single-blind, cross-over study Chronic bronchitis (MRC criteria) PEFR 148 ± 23 (L/min) n = 30
#Edwards 1976 Double-blind RCT Chronic bronchitis 1.46 L n = 82
Puchelle 1978 Double-blind RCT Chronic bronchitis (MRC criteria) Not stated n = 20
Grillage 1985 Double-blind, parallel-group, 
study
Chronic bronchitis (MRC criteria) PEFR 230 L/min n = 109
Allegra 1996 Double-blind, multicenter, 
parallel-group, trial
Chronic bronchitis (MRC criteria) SCMC 4.6 ± 1.9 n = 662
Placebo 3.3 ± 1.5
Tatsumi 2007 RCT COPD FEV1/FVC  70% SCMC 1.37 ± 0.07 n = 142
Placebo 1.2 ± 0.06
†Yasuda 2006b Double-blind RCT COPD 61.5% ± 2.2 n = 156
‡Zheng 2008 Double-blind RCT COPD (GOLD criteria) SCMC 43.93% ± 15.4 n = 709
Placebo 45.1% ± 15.23International Journal of COPD 2008:3(4) 667
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Abbreviations: C, carbocisteine (SCMC); Bm, bromhexine syrup; FEV1, forced expiratory volume in one second; MEFR, maximum expiratory ﬂ  ow rate; MRC, Medical Research 
Council; PEFR, peak expiratory ﬂ  ow rate; QoL, quality of life; RCT, randomized controlled trial; SGRQ, St George’s Respiratory Questionnaire; tds, 3-times daily;   VC, vital 
capacity; L/sec, liters per second; L/min, liters per minute.
Notes: #nebulized water produced equal results to SCMC.  p*   0.05; p**   0.01; p***   0.001; NS, no statistically signiﬁ  cant difference; †Inhaled or oral corticosteroids not 
permitted; ‡Oral corticosteroids at trial entry not permitted.16.7% of trial patients on ICS.
Duration Drug administration Outcomes Results
10 days 750 mg SCMC syrup tds vs bromhexine syrup Increased sputum volume  C = B
C = B
C = B (no change)
Increased sputum ‘pourability’
FEV1/PEFR
3 months 15 mL 5% SCMC syrup tds vs placebo Reduction in dyspnea C   p*
Sputum volume C   p*
Reduction in cough frequency and severity  C   p*
Ease of expectoration C   p*
Improvement in incapacity C   p*
3 months 3 g SCMC syrup daily vs placebo Sputum volume C   p*
Reduction in sputum viscosity C   p*
Reduction in dyspnea  C   p*
Increase in FEV1 C   p**
2 weeks 1 g SCMC tds vs placebo Reduction in FEV1/VC ratio p   C**
Other measures of airway obstruction 
(MEFR 25% and 50%)
NS
Sputum viscosity (increased) C   p*
Improved clinical status C   p*
6 months 750 mg SCMC tablets tds vs placebo Increase in PEFR at 1,2,3 and 5 months C   p*
Increase in PEFR at 4 and 6 months NS
Exacerbation rate NS
6 months 2.7 g SCMC daily vs placebo Patients with no exacerbations C   p***
Time to ﬁ  rst exacerbation C   p*
Mean days of acute respiratory illness C   p*
Mean days of antibiotic treatment C   p*
12 months 500 mg SCMC tds vs usual care Number of common colds C   p**
Number of exacerbations C   p** (RR 0.37)
Improvement in QoL (SGRQ) C   p**
Change in FEV1 C = p 
(no change)
12 months 1.5 g SCMC daily vs placebo Number of common colds C   p**
Number of exacerbations C   p** (RR 0.4)
12 months 500 mg SCMC tds vs placebo Number of exacerbations C   p**
(risk ratio 0.75)
Improvement in QoL (SGRQ) C   p***
Change in FEV1 C = p
(no change)International Journal of COPD 2008:3(4) 668
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